利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

12 条记录 (耗时 0.024 秒)

    Ouabain-specific monoclonal antibodies
    3.
    发明授权
    Ouabain-specific monoclonal antibodies 失效
    哇巴因特异性单克隆抗体

    公开(公告)号：US07348412B1

    公开(公告)日：2008-03-25

    申请号：US09412268

    申请日：1999-10-05

    申请人： Behnaz Parhami-Seren ,  Michael N. Margolies ,  Garner T. Haupert, Jr.

    发明人： Behnaz Parhami-Seren ,  Michael N. Margolies ,  Garner T. Haupert, Jr.

    IPC分类号： C07K1/00 ,  C07K16/00 ,  C07K21/08

    CPC分类号： C07K16/44 ,  A61K2039/505

    摘要： The invention relates to a monoclonal antibody or antigen binding fragment thereof having binding specificity for ouabain, wherein the antibody or antigen binding fragment does not crossreact with digoxin. Preferably the anti-ouabain monoclonal antibody can bind ouabain with an affinity of at least about 10−7M, preferably 10−8M, and more preferably 10−9M. The invention also relates to diagnostic and therapeutic uses of the monoclonal antibodies described herein.

    摘要翻译： 本发明涉及对哇巴因具有结合特异性的单克隆抗体或其抗原结合片段，其中抗体或抗原结合片段不与地高辛交联。 优选地，抗哇巴因单克隆抗体可以以至少约10 -7 M，优选10 -8 -8 M，更优选10 -6 M的亲和力结合哇巴因， 9， 本发明还涉及本文所述的单克隆抗体的诊断和治疗用途。

    Method for producing or enhancing a T-cell response against a target cell using a complex comprising an HLA class I molecule and an attaching means
    4.
    发明授权
    Method for producing or enhancing a T-cell response against a target cell using a complex comprising an HLA class I molecule and an attaching means 失效
    使用包含HLA I类分子和附着装置的复合物来产生或增强针对靶细胞的T细胞应答的方法

    公开(公告)号：US07264965B2

    公开(公告)日：2007-09-04

    申请号：US10116901

    申请日：2002-04-05

    申请人： Philip Michael Savage

    发明人： Philip Michael Savage

    IPC分类号： C12N5/00 ,  C12N5/16 ,  C07K21/08 ,  C07K16/18 ,  C07K1/10

    CPC分类号： C07K14/005 ,  A61K38/00 ,  A61K47/6849 ,  C07K14/70539 ,  C07K2319/00 ,  C12N2740/16222

    摘要： A complex including an HLA class I molecule and attaching means for selectively attaching the HLA class I molecule to a target is disclosed, and a method is provided for producing or enhancing an immunological response against a target cell, by attaching said complex to the target cell. Where the target cell is diseased, foreign, or malignant cell, this method may be used to promote lysis of the target cell by T cells in the immune system. Where the target cell is an antigen presenting cell, this method may be used to promote proliferation of specific T cell clones. Uses include prevention and treatment of diseases including cancer, leukaemia, infectious diseases, viral infections, such as HIV, bacterial infections, such as tuberculosis, and parasitic infections such as malaria.

    摘要翻译： 公开了包括HLA I类分子和用于将HLA I类分子选择性连接到靶的附着装置的复合物，并且提供了通过将所述复合物连接到靶细胞来产生或增强针对靶细胞的免疫应答的方法 。 靶细胞是患病，外源或恶性细胞时，该方法可用于促进免疫系统中的T细胞对靶细胞的裂解。 当靶细胞是抗原呈递细胞时，该方法可用于促进特异性T细胞克隆的增殖。 用途包括预防和治疗包括癌症，白血病，传染病，艾滋病病毒感染，细菌感染如结核病以及寄生虫感染如疟疾在内的疾病。

    Interleukin-1β converting enzyme like apoptotic protease-6
    8.
    发明授权
    Interleukin-1β converting enzyme like apoptotic protease-6 有权
    白细胞介素-1β转换酶如凋亡蛋白酶-6

    公开(公告)号：US06890721B1

    公开(公告)日：2005-05-10

    申请号：US09961201

    申请日：2001-09-24

    申请人： Vishva M. Dixit ,  Wei-Wu He ,  Kristine K. Kikly ,  Steven M. Ruben

    发明人： Vishva M. Dixit ,  Wei-Wu He ,  Kristine K. Kikly ,  Steven M. Ruben

    IPC分类号： A61K38/00 ,  A61K48/00 ,  C12N9/64 ,  C07K16/40 ,  C07K16/18 ,  C12N5/12 ,  G01N33/53 ,  C07K21/08

    CPC分类号： C12N9/6475 ,  A61K38/00 ,  A61K48/00

    摘要： Human ICE LAP-6 polypeptides and DNA (RNA) encoding such ICE LAP-6 and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilize such ICE LAP-6 for the treatment of a susceptibility to viral infection, tumorogenesis and to diseases and defects in the control embryogenesis and tissue homeostasis, and the nucleic acid sequences described above may be employed in an assay for ascertaining such susceptibility. Antagonists against such ICE LAP-6 and their use as a therapeutic to treat Alzheimer's disease, Parkinson's disease, rheumatoid arthritis, septic shock, sepsis, stroke, chronic inflammation, acute inflammation, CNS inflammation, osteoporosis, ischemia reperfusion injury, cell death associated with cardiovascular disease, polycystic kidney disease, apoptosis of endothelial cells in cardiovascular disease, degenerative liver disease, MS, ALS, cererbellar degeneration ischemic injury, myocardial infarction, AIDS, myelodysplastic syndromes, aplastic anemia, male pattern baldness, and head injury damage are also disclosed. Also disclosed are diagnostic assays for detecting diseases related to mutations in the nucleic acid sequences and altered concentrations of the polypeptides. Also disclosed are diagnostic assays for detecting mutations in the polynucleotides encoding the interleukin-1 beta converting enzyme apoptosis proteases and for detecting altered levels of the polypeptide in a host.

    摘要翻译： 公开了人ICE LAP-6多肽和编码这种ICE LAP-6的DNA（RNA）和通过重组技术产生这种多肽的方法。 还公开了利用这种ICE LAP-6用于治疗对病毒感染，肿瘤发生的易感性以及控制胚胎发生和组织稳态中的疾病和缺陷的方法，并且上述核酸序列可用于确定 这种敏感性。 对抗这种ICE LAP-6的拮抗剂及其作为治疗性阿尔茨海默病，帕金森病，类风湿性关节炎，败血性休克，败血症，中风，慢性炎症，急性炎症，CNS炎症，骨质疏松症，缺血再灌注损伤，与 还披露了心血管疾病，多囊肾病，心血管疾病中的内皮细胞凋亡，退行性肝病，MS，ALS，小脑变性缺血性损伤，心肌梗死，AIDS，骨髓增生异常综合征，再生障碍性贫血，男性型秃发和头部损伤损伤 。 还公开了用于检测与核酸序列中的突变和多肽的改变的浓度相关的疾病的诊断测定。 还公开了用于检测编码白细胞介素-1β转换酶凋亡蛋白酶的多核苷酸中的突变并用于检测宿主中多肽的改变水平的诊断测定法。

    Methods for treating autoimmune and chronic inflammatory conditions using antagonists of CD30 or CD30L
    10.
    发明授权
    Methods for treating autoimmune and chronic inflammatory conditions using antagonists of CD30 or CD30L 有权
    使用CD30或CD30L拮抗剂治疗自身免疫性和慢性炎性病症的方法

    公开(公告)号：US07273609B2

    公开(公告)日：2007-09-25

    申请号：US11506645

    申请日：2006-08-18

    申请人： Kendall M. Mohler ,  Dauphine S. Barone ,  Mary K. Kennedy

    发明人： Kendall M. Mohler ,  Dauphine S. Barone ,  Mary K. Kennedy

    IPC分类号： A61K39/395 ,  C07K21/08 ,  C07K16/22

    CPC分类号： C07K16/2875 ,  A61K2039/505

    摘要： The invention provides methods of treating autoimmune and chronic inflammatory conditions by administering agents that hinder the CD30/CD30L interaction, combination treatments, and methods of treating conditions resistant to treatment with TNFα inhibitors by administering agents that inhibit signal transduction by CD30 or IL-1. Included also are treatments involving concurrently administering agents that block the CD30/CD30L interaction and agents that antagonize the IL-4/IL-4R interaction. Additionally provided is an animal model for screening candidate agents for their efficacy in treating conditions that are resistant to treatment with TNFα inhibitors.

    摘要翻译： 本发明提供了通过施用抑制CD30 / CD30L相互作用的药剂，联合治疗和通过用抑制CD30或IL-1信号转导的药物来治疗耐TNFα抑制剂治疗条件的方法来治疗自身免疫性和慢性炎性病症的方法。 还包括涉及同时施用阻断CD30 / CD30L相互作用的药剂和拮抗IL-4 / IL-4R相互作用的药物的治疗。 另外提供了用于筛选候选试剂在治疗对TNFalpha抑制剂治疗有抗性的病症方面的功效的动物模型。